Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Jul 19

PMID 34276646

Citations 13

Authors

Chaojun Hu

Siting Li

Zhijuan Xie

Hanxiao You

Hui Jiang

Yu Shi

Wanting Qi

Jiuliang Zhao

Qian Wang

Xinping Tian

Mengtao Li

Yan Zhao

Xiaofeng Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Diagnosis of antiphospholipid syndrome (APS) is based on the positivity of laboratory criteria antiphospholipid antibodies (aPLs). Test results for aPLs could be contradictory among different detection methods as well as commercial manufacturers. This study aimed to assess and compare the diagnostic and analytic performances of four commercial assays prevalently used in China.

Methods: A total of 313 patients including 100 patients diagnosed with primary APS, 52 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum IgG, IgM, and IgA for aCL, and a2GPI antibodies were detected with two ELISA and two CLIA systems, and test system with the best diagnostic value was explored of its correlation with key clinical features.

Results: CLIA by YHLO Biotech Co. was considered as the system with the best predictive power, where 58.55 and 57.89% of APS patients were positive for aCL or a2GPI for at least one antibody (IgG or IgM or IgA). Overall, CLIA showed better performance characteristics than traditional ELISA test systems.

Conclusion: CLIA was considered as a better platform for aPL detection in APS diagnosis. A combination of other detection platforms could assist in differential diagnosis as well as in identifying high-risk patients.

Citing Articles

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.

Huang C, Ding Y, Chen Z, Wu L, Wei W, Zhao C BMC Med. 2025; 23(1):8.

PMID: 39757171 PMC: 11702278. DOI: 10.1186/s12916-024-03843-9.

Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE.

Wang C, Jiang H, Chen S, Zhao Y, Li J, Huang C Clin Exp Med. 2024; 24(1):130.

PMID: 38888664 PMC: 11189343. DOI: 10.1007/s10238-024-01400-5.

Antiphospholipid antibodies in patients with antiphospholipid syndrome.

Dodig S, cepelak I Biochem Med (Zagreb). 2024; 34(2):020504.

PMID: 38882589 PMC: 11177653. DOI: 10.11613/BM.2024.020504.

Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.

Li Q, Li J, Zhou M, Ge Y, Liu Z, Li T Front Immunol. 2024; 15:1354349.

PMID: 38707895 PMC: 11066154. DOI: 10.3389/fimmu.2024.1354349.

Proteomics analysis of plasm exosomes in early pregnancy among normal pregnant women and those with antiphospholipid syndrome.

Sun Y, Wang Z, Li J, Wang T, Tan Y Heliyon. 2024; 10(8):e29224.

PMID: 38655308 PMC: 11035995. DOI: 10.1016/j.heliyon.2024.e29224.

References

Tozzoli R, Villalta D . Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev. 2013; 13(1):59-63. DOI: 10.1016/j.autrev.2013.08.007. View

Devreese K . How to Interpret Antiphospholipid Laboratory Tests. Curr Rheumatol Rep. 2020; 22(8):38. DOI: 10.1007/s11926-020-00916-5. View

Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N . Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2009; 8(2):237-42. DOI: 10.1111/j.1538-7836.2009.03674.x. View

Garcia D, Erkan D . Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018; 378(21):2010-2021. DOI: 10.1056/NEJMra1705454. View

Grossi V, Infantino M, Benucci M, Li Gobbi F, Bandinelli F, Damiani A . Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2-Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays. Immunol Invest. 2019; 49(1-2):58-68. DOI: 10.1080/08820139.2019.1647233. View

Thaler M, Bietenbeck A, Steigerwald U, Buttner T, Schierack P, Lindhoff-Last E . Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS One. 2019; 14(7):e0220033. PMC: 6655644. DOI: 10.1371/journal.pone.0220033. View

Lockshin M, Kim M, Laskin C, Guerra M, Branch D, Merrill J . Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012; 64(7):2311-8. PMC: 3357451. DOI: 10.1002/art.34402. View

Decavele A, Schouwers S, Devreese K . Evaluation of three commercial ELISA kits for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2010; 33(1):97-108. DOI: 10.1111/j.1751-553X.2010.01259.x. View

Van Hoecke F, Persijn L, Decavele A, Devreese K . Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012; 34(6):630-40. DOI: 10.1111/j.1751-553X.2012.01448.x. View

10.

Devreese K . Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014; 36(3):352-63. DOI: 10.1111/ijlh.12234. View

11.

Devreese K . Testing for antiphospholipid antibodies: Advances and best practices. Int J Lab Hematol. 2020; 42 Suppl 1:49-58. DOI: 10.1111/ijlh.13195. View

12.

Wang D, Lv W, Zhang S, Zhang J . Advances in the Research on Anticardiolipin Antibody. J Immunol Res. 2019; 2019:8380214. PMC: 6914984. DOI: 10.1155/2019/8380214. View

13.

Hu C, Li X, Zhao J, Wang Q, Li M, Tian X . Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. Front Immunol. 2020; 11:568503. PMC: 7573363. DOI: 10.3389/fimmu.2020.568503. View

14.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

15.

Hughes G, Khamashta M . Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003; 62(12):1127. PMC: 1754381. DOI: 10.1136/ard.2003.006163. View

16.

Persijn L, Decavele A, Schouwers S, Devreese K . Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res. 2011; 128(6):565-9. DOI: 10.1016/j.thromres.2011.04.004. View

17.

Zhou J, Hou X, Zhang H, Wang T, Cui L . The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies. Med Sci Monit. 2018; 24:6816-6822. PMC: 6180949. DOI: 10.12659/MSM.910369. View

18.

Mahler M, Bentow C, Serra J, Fritzler M . Detection of autoantibodies using chemiluminescence technologies. Immunopharmacol Immunotoxicol. 2015; 38(1):14-20. PMC: 4819877. DOI: 10.3109/08923973.2015.1077461. View

19.

De Carolis S, Tabacco S, Rizzo F, Giannini A, Botta A, Salvi S . Antiphospholipid syndrome: An update on risk factors for pregnancy outcome. Autoimmun Rev. 2018; 17(10):956-966. DOI: 10.1016/j.autrev.2018.03.018. View

20.

Paule R, Morel N, Le Guern V, Fredi M, Coutte L, Belhocine M . Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. Autoimmun Rev. 2018; 17(9):866-872. DOI: 10.1016/j.autrev.2018.03.011. View